- Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are highly prevalent multi-system disorders that represent major threats to public health.
- Improved knowledge of the metabolic etio-pathophysiology of NAFLD/NASH has stimulated intense efforts to develop safe and effective pharmacological interventions. Many of the drugs that have been evaluated as potential treatments for NAFLD/NASH or are currently in development are classified as having metabolic or cardiometabolic actions
- We propose a collaborative approach to the development of new pharmacotherapies for NAFLD/NASH that brings together expertise in clinical hepatology, diabetes and human metabolism
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information, such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.
Analytics cookies used:
- Google Tag Manager
- GStatic
- Google AdWords
Please enable Strictly Necessary Cookies first so that we can save your preferences!
Privacy Policy
More information about our Cookie Policy can be found within our Privacy Policy